A Safety and Activity Study of NS2 in Subjects With Allergic Conjunctivitis
Study sponsor: Aldeyra Therapeutics, Inc. · ALDX
Primary completion is the date data collection ends for the main study measures, not when results are published.
Primary completion2015-12Actual
Enrollment · participants100Actual
Source updated2023-12-05Last update listed in the registry record
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.